Experimental studies and phase II trial of bisantrene in advanced urothelial malignancies.
A phase II trial with bisantrene was performed simultaneously against urothelial tumors in nude mice and in patients with metastatic transitional cell carcinoma. The starting dose was 260 mg/m2, intravenously, every 3 weeks. No responses were seen in the in vivo animal study or in 13 treated patients.
D000368:Aged; D000818:Animals; D000873:Anthracenes / Q000009:adverse effects / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008875:Middle Aged; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D000873:Anthracenes; D000903:Antibiotics, Antineoplastic; C031404:bisantrene